236 Views | 105 Downloads
Corresponding author: Brad Wertheim MD, 15 Francis Street, Boston MA, 02115 bwertheim@partners.org, tel: 617-732-6770, fax 617-582-6102.
The authors would like to thank Chris Lofgren for his assistance with laboratory data collection and Drs. Arjun Rao and Ciaran McMullan for their assistance with study implementation.
The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.
Gabriela Motyckova was paid for work for the blinatumumab ALL Advisory Board in 2015.
All other authors reported no conflicts of interest.
In addition, they gratefully acknowledge the residents, faculty, and staff of the MGH Department of Medicine and Internal Medicine Residency Training Program for their assistance and financial support of this project.
This work was conducted with support from Harvard Catalyst, the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102), and financial contributions from Harvard University and its affiliated academic healthcare centers.
Bradley Wertheim was paid by the Massachusetts General Hospital Department of Medicine for his work as a research assistant on this study.
Eric Macklin is supported by NIH grant UL1 TR001102, and is a paid DSMB member of Acorda Therapeutics and Shire Human Genetic Therapies.
© 2016 Elsevier Inc.